Novartis AG Common Stock (NVS)

Total Liabilities

$80.09B

Quarterly · Period ending: · USD

NVS logo

NVS Total Liabilities

Latest reported$80.09B
NVS Quarterly Total Liabilities ($15.58B → $80.09B)
High-resolution chart · PNG

NVS total liabilities history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Novartis AG Common Stock Total Liabilities — Quarterly (USD)
Period endingTotal Liabilities (USD)
80,087,321,000
79,605,000,000
69,020,119,000
62,537,000,000
62,341,000,000
61,489,000,000
58,120,000,000
60,083,000,000
55,603,000,000
54,578,000,000
57,073,887,621
74,452,000,000
59,048,000,000
60,099,000,000
62,342,150,867
57,566,000,000
59,904,000,000
63,514,000,000
68,062,000,000
64,272,000,000
69,887,000,000
71,163,000,000
75,523,000,000
75,124,000,000
69,878,000,000
72,120,000,000
62,861,728,310
63,373,000,000
64,790,000,000
90,639,000,000
66,871,000,000
64,975,000,000
65,157,000,000
64,313,000,000
58,852,000,000
62,602,000,000
63,771,000,000
64,340,000,000
55,233,000,000
58,941,000,000
58,904,000,000
60,559,000,000
54,434,000,000
56,142,000,000
56,581,000,000
58,491,000,000
54,543,000,000
53,953,000,000
55,251,000,000
54,996,000,000
51,782,000,000
52,415,000,000
51,444,000,000
53,863,000,000
54,997,000,000
54,014,000,000
54,251,000,000
56,210,000,000
51,556,000,000
55,236,000,000
58,822,000,000
61,878,000,000
53,549,000,000
58,410,000,000
41,108,000,000
40,579,000,000
38,043,000,000
37,373,000,000
33,786,000,000
31,742,000,000
27,862,000,000
31,283,000,000
31,794,000,000
27,052,000,000
26,056,000,000
27,443,000,000
26,957,000,000
27,822,000,000
26,714,000,000
28,272,000,000
28,765,000,000
25,094,000,000
24,568,000,000
22,932,000,000
22,650,000,000
20,184,000,000
20,548,000,000
18,410,000,000
18,391,000,000
18,942,000,000
18,798,000,000
17,887,000,000
19,218,000,000
18,649,000,000
16,734,000,000
15,249,000,000
15,138,000,000
14,747,000,000
13,919,000,000
12,960,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.